Literature DB >> 1987054

Interleukin-6 response to deliberate colonization of the human urinary tract with gram-negative bacteria.

S Hedges1, P Anderson, G Lidin-Janson, P de Man, C Svanborg.   

Abstract

Intravesical inoculation of patients with Escherichia coli provided an opportunity to examine the interleukin-6 (IL-6) response to a gram-negative bacterial urinary tract infection in humans. All patients secreted IL-6 as a result of infection. Urinary IL-6 was not continuously secreted but appeared as a series of similar peaks during the first 48 h after infection. There was no significant difference in the ability to trigger IL-6 secretion between isogenic adhering or nonadhering strains, but a threshold concentration of 10(5) bacteria per ml of urine was necessary to fully stimulate IL-6 secretion. There was no detectable increase in IL-6 levels in the serum of the colonized individuals, suggesting mainly local IL-6 production. These results demonstrate that IL-6 is a part of the human mucosal response to gram-negative urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1987054      PMCID: PMC257757          DOI: 10.1128/iai.59.1.421-427.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Autoregulation of interleukin 1 production.

Authors:  J C Manson; J A Symons; F S Di Giovine; S Poole; G W Duff
Journal:  Eur J Immunol       Date:  1989-02       Impact factor: 5.532

2.  Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man.

Authors:  Y Fong; L L Moldawer; M Marano; H Wei; S B Tatter; R H Clarick; U Santhanam; D Sherris; L T May; P B Sehgal
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

3.  Receptors for pyelonephritogenic Escherichia coli in primates.

Authors:  J A Roberts; B Kaack; G Källenius; R Möllby; J Winberg; S B Svenson
Journal:  J Urol       Date:  1984-01       Impact factor: 7.450

4.  Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice.

Authors:  L Hagberg; R Hull; S Hull; J R McGhee; S M Michalek; C Svanborg Edén
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

5.  Construction and expression of recombinant plasmids encoding type 1 or D-mannose-resistant pili from a urinary tract infection Escherichia coli isolate.

Authors:  R A Hull; R E Gill; P Hsu; B H Minshew; S Falkow
Journal:  Infect Immun       Date:  1981-09       Impact factor: 3.441

6.  Non-antibiotic prevention of urinary tract infection.

Authors:  L Hagberg; H Leffler; C Svanborg Edén
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

7.  Contribution of adhesion to bacterial persistence in the mouse urinary tract.

Authors:  L Hagberg; R Hull; S Hull; S Falkow; R Freter; C Svanborg Edén
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

8.  Bacterial attachment and inflammation in the urinary tract.

Authors:  P de Man; U Jodal; K Lincoln; C S Edén
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

9.  B cell growth and differentiation activity of interleukin-HP1 and related murine plasmacytoma growth factors. Synergy with interleukin 1.

Authors:  A Vink; P G Coulie; P Wauters; R P Nordan; J Van Snick
Journal:  Eur J Immunol       Date:  1988-04       Impact factor: 5.532

Review 10.  Physiological responses to cachectin.

Authors:  K J Tracey; S F Lowry; A Cerami
Journal:  Ciba Found Symp       Date:  1987
View more
  65 in total

1.  Antimicrobial activity of intraurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection.

Authors:  T Asahara; K Nomoto; M Watanuki; T Yokokura
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Pharmacologic Basis for the Treatment of Pyelonephritis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

Review 3.  Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Authors:  Thomas J Hannan; Makrina Totsika; Kylie J Mansfield; Kate H Moore; Mark A Schembri; Scott J Hultgren
Journal:  FEMS Microbiol Rev       Date:  2012-05       Impact factor: 16.408

4.  Sequential measurements of chemokines in urosepsis and experimental endotoxemia.

Authors:  D P Olszyna; J M Prins; P E Dekkers; E De Jonge; P Speelman; S J Van Deventer; T Van Der Poll
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

Review 5.  Prevention of catheter-associated urinary tract infection.

Authors:  Barbara W Trautner; Richard A Hull; Rabih O Darouiche
Journal:  Curr Opin Infect Dis       Date:  2005-02       Impact factor: 4.915

6.  Impaired cytokine expression, neutrophil infiltration and bacterial clearance in response to urinary tract infection in diabetic mice.

Authors:  Ahmet Ozer; Cengiz Z Altuntas; Fuat Bicer; Kenan Izgi; Scott J Hultgren; Guiming Liu; Firouz Daneshgari
Journal:  Pathog Dis       Date:  2015-02-05       Impact factor: 3.166

7.  Effect of inactivation of the global oxidative stress regulator oxyR on the colonization ability of Escherichia coli O1:K1:H7 in a mouse model of ascending urinary tract infection.

Authors:  James R Johnson; Connie Clabots; Henry Rosen
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

8.  Uroepithelial cells are part of a mucosal cytokine network.

Authors:  S Hedges; W Agace; M Svensson; A C Sjögren; M Ceska; C Svanborg
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

9.  Induction and suppression of cytokine release (tumour necrosis factor-alpha; interleukin-6, interleukin-1 beta) by Escherichia coli pathogenicity factors (adhesions, alpha-haemolysin).

Authors:  B König; W König
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

10.  Local cytokine production in a murine model of Escherichia coli pyelonephritis.

Authors:  H S Rugo; P O'Hanley; A G Bishop; M K Pearce; J S Abrams; M Howard; A O'Garra
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.